Latest Website Changes

Revised daptomycin guidance document published

Updated guidance document on Endocarditis published

Updated guidance on S. maltophilia

Breakpoint tables for interpretation of MICs for antifungal agents have been updated

Version 12.0, valid from 2025-06-26

Rationale documents for antifungal agents have been updated

Rezafungin, Isavuconazole, Micafungin, Anidulafungin, Amphotericin B, Flucytosine (5-fluorocytosine)

EUCAST accepts the use of MH-S

MH-F based on horse blood can be exchanged for MH-S based on sheep blood - with the exception of Haemophilus

Warning against the use of gradient tests for determining benzylpenicillin MICs in S. pneumoniae - updated August 2025

RAST tables updated

Updated guidance on Infective endocarditis

SOP 9 updated

SOP 9.3 updated to 9.4.

VetCAST Rationale documents published

Daptomycin in Enterococcus

Daptomycin in endocarditis and bloodstream infections caused by enterococci (updated April 2025)

RAST breakpoints and methods updated

The breakpoint table was updated - new information on how to screen for and characterize benzylpenicillin resistance in Streptococcus pneumoniae added. - files describing the correlation between RAST zone diameters and reference MIC values were updated - methods document updated - document describing the detection of specific resistance mechanisms updated - document proposing how to implement RAST in the clinical laboratory updated.

All calibration files - MIC vs. zone diameters - updated for 2025

All calibration files updated for 2025. For 2025 S. dysgalactiae is added

Update of SOP 12

The SOP 12 on the "Process to Submit Disk Content (Potency) Data for Joint CLSI-EUCAST Working Group Review and Approval" was updated to 12.1

Updated guidance on the use cephalosporins for S. aureus

M. tuberculosis MIC reference testing available from EUCAST AMST

Following standard consultation, the EUCAST AMST reference protocol MIC determination of M. tuberculosis has now been released in the Mycobacteria methods section

Rationale document template for pharmaceutical companies

Companies are requested to complete a "company rationale document" to aid the EUCAST process. A template for how has been available for many years. It is now revised.

ECOFFinder software removed from website

The previously available ECOFFinder program is no longer accessible on the EUCAST website because, according to EUCAST procedures (SOP 10.2), setting ECOFFs or TECOFFs on single or already aggregated distributions is not acceptable according to EUCAST recommendations. Software and procedures to set individual ECOFFs on 5 or preferably more accepted distributions result in mean ECOFFs with confidence limits and an analysis of the quality of the procedure leading to the establishment of a formal ECOFF recognized by EUCAST in the processes for setting breakpoints, screening for resistance etc.

NAC update for Greece

The presentation of the Greek NAC updated

SOP 11 revised

Clinical breakpoints 2025

Yearly update of EUCAST breakpoint tables. News highlighted in pale yellow or with underlining of text.

Updated documents on disk diffusion methodology

QC criteria for cefepime-enmetazobactam and aztreonam-avibactam

Breakpoint table 15.0 on consultation

Endocarditis AST guidelines

Guidance for the use of the new endocarditis breakpoints (released as part of the v 15.0 (2025) breakpoint table) is released.

Antifungal breakpoints and updated 2 Dec 2024

The breakpoint tables for antifungal agents have been revised.

Antifungal overview of breakpoints and ECOFFs revised

Anidulafungin and Micafungin rationale documents updated 2024

Endocarditis breakpoints

Following the now finalised consultation, the comments from colleagues and responses from EUCAST are now published.

Updated guidance on S. maltophilia

Rezafungin Rationale Document published

Response to public consultation

EUCAST comments and responses ​​​​​​​to the public consultation on changing breakpoints for S. pneumoniae and Streptococcus viridans published.

RAST tables - Error related to Acinetobacter corrected

An error related to recommendations for Acinetobacter baumannii and ciprofloxacin corrected.

Aminoglycoside rationale documents updated

General consultation on proposed breakpoints for endocarditis

The public consultation is open between 14 Sept and 25 Oct, 2024.

Cefiderocol has been addded to "When there are no breakpoints"

New Rationale Document

RDs for aztreonam-avibactam and cefepime-enmetazobactam available

RAST from EUCAST with breakpoints for Salmonella enterica

EUCAST has developed the Enterobacterales RAST further to include 4, 6, 8 and 16-20 h breakpoints also for Salmonella enterica. Some QC criteria were also updated.

Expert rules updated

Expert rules​​​​​​​ updated for Enterobacterales and Enterococcus.

Updated guidance document

"Intravenous use of fosfomycin" updated 28 May, 2024. See guidance documents.

Aztreonam-avibactam and cefepime-enmetazobactam breakpoints available

Breakpoints published as addenda to the regular breakpoint table 14.0, 2024.

The Belgian NAC presented

The Belgian NAC (National AST Committee) is presented.

New consultations

New consultation published.

EUCAST advice on the development of reference methods for MIC testing of new agents

The development of new agents require agreement and acceptance of the data generated in support of decisions on clinical breakpoints, wild type MIC distributions, ECOFFs and routine susceptibility testing correlates. EUCAST and CLSI both favour the unadulterated use of ISO recommended reference broth microdilution for this purpose, and only occasionally is there good reason to deviate from this. When this is considered necessary it is strongly adviced that this is with the agreement and full understanding of standards committees and agencies, such as CLSI, EUCAST, FDA and EMA.

When there are no breakpoints - revised 29 February 2024

Advising pharmaceutical industry

The advice to pharmaceutical industry has been further developed. Go to the "Information for industry" page.

Rezafungin Rationale Document published

Updated guidance on ATU

Revised "EUCAST response to the fosfomycin consultation"

Because of a printing error in this document a new version was uploaded.

ECCMID 2023 EUCAST posters available

Maps updated for 2024 EUCAST uptake

Graphs to illustrate ATUs updated 2024

EUCAST provides a yearly update of the ATUs in relation to zone diameter and MIC distributions. The 2024 update now available.

Files demonstrating the correlation between MIC and zone diameters now updated

Several Rationale Documents updated